Fig. 2From: Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemiaRAASi change following an HK episode in (a) the US and (b) Japan. ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, ARNi angiotensin receptor-neprilysin inhibitor, HK hyperkalemia, MRA mineralocorticoid receptor antagonist, RAASi renin-angiotensin-aldosterone system inhibitorBack to article page